Hepatocellular carcinoma (HCC) and hepatic metastasis (HM) are associated with distinct treatment and prognosis, while the differential diagnosis of HCC and HM still remains challenging. This study aims to explore the value of mDIXON quant and IVIM imaging in the differential diagnosis of HCC and HM. Results shown that the combination of R2*and IVIM measurements may offer a good biomarker for differential diagnosis of HCC and HM.
This abstract and the presentation materials are available to members only; a login is required.